ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0429 • ACR Convergence 2020

    Prothrombotic Antiphospholipid Antibodies in COVID-19

    Yu Zuo1, Shanea Estes2, Alex Ghandi3, Srilakshmi Yalavarthi3, Ramadan Ali3, Shi Hui3, Gautam Sule3, Kelsey Gockman3, Jacqueline Madison3, Melanie Zuo3, Wrenn Woodard3, Sean Lezak3, Njira Lugogo3, Yogendra Kanthi4 and Jason Knight1, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, 4Division of Cardiovascular Medicine, Ann Arbor

    Background/Purpose: Patients with coronavirus disease 19 (COVID-19) are at high risk for thrombosis of arteries and veins. At the same time, COVID-19 lung histopathology has…
  • Abstract Number: 0430 • ACR Convergence 2020

    Outcomes of Coronavirus Disease 2019 Infection Among Patients Living with Rheumatic Diseases: A Matched Cohort Study from a US Multi-Center Research Network

    Kristin D'Silva1, April Jorge1, Na Lu2, Yuqing Zhang3, Zachary Wallace4 and Hyon Choi5, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, BC, Canada, 3Massachusetts General Hospital, Quincy, MA, 4Massachusetts General Hospital, Newton, MA, 5Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Whether patients living with systemic autoimmune rheumatic diseases (SARDs) suffer from more severe complications of Coronavirus Disease 2019 (COVID-19) infection remains unknown.Methods: We conducted…
  • Abstract Number: 0431 • ACR Convergence 2020

    Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients

    Elizabeth Park1, Jon Giles2, Thania Perez-Recio1, Paloma Pina3, Christopher Depender1, Joan Bathon1 and Laura Geraldino-Pardilla4, 1Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, 2Columbia University, New York, NY, 3Cardiac Electrophysiology, Northwestern Medicine, Chicago, IL, 4Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York

    Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis…
  • Abstract Number: 0432 • ACR Convergence 2020

    The Effect on Renal Function of the Complement C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

    Peter Merkel1, Pirow Bekker2, Huibin Yue2, Catherine Kelleher2, Thomas Schall2 and David Jayne3, 1University of Pennsylvania, Philadelphia, PA, 2ChemoCentryx, Mountain View, CA, 3Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom

    Background/Purpose: Avacopan, a novel, orally-administered selective antagonist of C5aR, was recently evaluated in a pivotal Phase 3 randomized clinical trial where its use in patients…
  • Abstract Number: 0433 • ACR Convergence 2020

    Racial Disparities and New SLE-Specific Predictors of Stroke and Ischemic Heart Disease in Patients with Lupus

    Shivani Garg1, Christie Bartels2, Gaobin Bao3, Cristina Drenkard4 and S. Sam Lim3, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI, 3Emory University, Atlanta, GA, 4Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA

    Background/Purpose: In the US, cardiovascular disease (CVD) is the leading cause of disparities in life expectancy between black and white populations. We recently reported a…
  • Abstract Number: 0434 • ACR Convergence 2020

    Changes in Mental Health During the COVID-19 Pandemic Among Individuals with Rheumatic Disease

    Patricia Katz1, Sofia Pedro2, Kristin Wipfler3, Teresa Simon4, Yomei Shaw5, Adam Cornish6 and Kaleb Michaud7, 1University of California, San Francisco, Novato, CA, 2FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, 3FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 4Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ, 5Forward, The National Databank for Rheumatic Diseases, East Lansing, MI, 6FORWARD, 68134, NE, 7University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Symptoms of both depression and anxiety are often elevated among individuals with rheumatic conditions, and stress levels may play a role in each.  Depression,…
  • Abstract Number: 0435 • ACR Convergence 2020

    Low Incidence of Coronavirus Disease 2019 (COVID-19) Infection in Patients on Biologic Infusion Therapies at a Community Rheumatology Practice

    Julie Keegan Strosser1, Ronald Yglesias2 and Norman Gaylis1, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2Arthritis & Rheumatic Disease Specialties, Hialeah, FL

    Background/Purpose: Following the first documented Florida case of COVID-19 on March 1, 2020, our community rheumatology practice continued to administer biologic infusion therapy with concern…
  • Abstract Number: 0436 • ACR Convergence 2020

    The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research

    Karin Tse1, Sanjyot Sangodkar2, Kathleen Arntsen3, Sang-Cheol Bae4, Lauren Bloch2, Ian Bruce5, Erin Connolly-Strong6, Karen Costenbader7, Thomas Dörner8, Sydney Evans9, Timothy Franson2, Kenneth Getz10, Amy Kao11, Kenneth Kalunian12, Bradley Dickerson13, Susan Manzi14, Eric Morand15, Yaritza Peña10, Sandra Raymond16, Brad Rovin17, Laura Schanberg18, Joan Von Feldt19, Victoria Werth20, Angel Williams21, David Zook2 and Leslie Hanrahan16, 1Lupus Foundation of America, DC, WA, 2Faegre Drinker Consulting, Washington, DC, 3Lupus and Allied Diseases Association, Inc., Verona, NY, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 5Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6Mallinckrodt, Austin, TX, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 8DRFZ and Charité University Hospitals, Berlin, Germany, 9Lupus Patient Representative, Riverdale, MD, 10Tufts Center for the Study of Drug Development, Boston, MA, 11EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 12University of California San Diego, La Jolla, CA, 13Aurinia Pharmaceuticals, Fort Washington, PA, 14Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 15Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 16Lupus Foundation of America, Washington, DC, 17The Ohio State University, Columbus, 18Duke University Medical Center, Durham, NC, 19GlaxoSmithKline, WILMINGTON, DE, 20University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 21Lupus Patient Representative, Richmond, VA

    Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…
  • Abstract Number: 0437 • ACR Convergence 2020

    Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting

    Jun Chu1, Sarthak Gupta1, Zerai Manna2, Michael Davis1, Yenealem Temesgen-Oyelakin1, Elaine Poncio1, Isabel Ochoa1, Laura Lewandowski3, Mariana Kaplan4, Alan Decherney1 and Sarfaraz Hasni2, 1National Institutes of Health, Bethesda, MD, 2Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, 3NIAMS, NIH, Rockville, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) predominantly affects women of childbearing age. Women affected by SLE have higher risk for infertility, miscarriages, and other pregnancy complications…
  • Abstract Number: 0438 • ACR Convergence 2020

    Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Large Private Rheumatology Practice

    Jessica Farrell1, Mitchell Miller1, Kelsey Hennig2, Kelley Powers3, Sooyeon Kwon4, Denae Moyer5, Kathryn French5, Angela Citta5 and Jacqueline Cleary1, 1Albany College of Pharmacy and Health Sciences, Albany, NY, 2Albany College of Pharmacy and Health Sciences, New Lebanon, NY, 3The Center for Rheumatology, Delanson, NY, 4Albany Stratton VA Hospital, Loudonville, NY, 5Albany College of Pharmacy and Health Sciences, Albany

    Background/Purpose: With the evolution of DMARDs, the need for opioids in the treatment of rheumatic diseases has decreased. However, rheumatology professionals are often presented with…
  • Abstract Number: 0439 • ACR Convergence 2020

    Hurried Communication and Low Patient Self-Efficacy Are Associated with Persistent Non-Adherence to SLE Medications

    Ann Cameron Barr1, Megan Clowse2, Amanda Eudy3, Jennifer Rogers4, Rebecca Sadun3, Lisa Criscione-Schreiber5, Jayanth Doss3, Lena Eder6, Mithu Maheswaranathan3, Amy Corneli7, Hayden Bosworth7 and Kai Sun3, 1Duke University Hospital, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University, Durham, NC, 4Duke, Durham, NC, 5Duke University School of Medicine, Durham, NC, 6Duke University Hospital, Chapel Hill, NC, 7Duke University, Durham

    Background/Purpose: Medication non-adherence is common among SLE patients and contributes to poor outcomes. Underrepresented racial minorities have disproportionately lower rates of medication adherence and often…
  • Abstract Number: 0440 • ACR Convergence 2020

    Representation of Women as Authors of Rheumatology Research Articles

    Ekta Bagga1, Sarah Stewart2, Gregory Gamble1, Janine Hill1, Andrew Grey1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2The University of Auckland, Auckland, New Zealand

    Background/Purpose: In academic medicine, journal article authorship is central to career advancement and promotion. This study aimed to examine the contemporary representation of women as…
  • Abstract Number: 0441 • ACR Convergence 2020

    Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus

    Kreager Taber1, Jessica Williams1, Weixing Huang2, Katherine McLaughlin1, Christine Vogeli3, Rebecca Cunningham1, Lisa Wichmann1 and Candace Feldman4, 1Brigham and Women's Hospital, Boston, MA, 2Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, 3Massachusetts General Hospital, Boston, MA, 4Brigham and Women's Hospital, Boston

    Background/Purpose: The burden of systemic lupus erythematosus (SLE) falls disproportionately on racial/ethnic minorities and individuals of lower socioeconomic status who often receive fragmented, inconsistent care.…
  • Abstract Number: 0442 • ACR Convergence 2020

    Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate

    Maria Antonelli1 and Nora Singer2, 1MHMC/CWRU, Cleveland, OH, 2The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: In the initial months of the SARS CoV2/COVID19 pandemic, broad use of off-label therapy with hydroxychloroquine (HCQ) was prescribed to reduce CoV2-related morbidity and…
  • Abstract Number: 0443 • ACR Convergence 2020

    Impact of the COVID-19 Pandemic on Racial and Ethnic Minority Groups Diagnosed with Rheumatic Diseases

    Emily Sirotich1, Teresa Semalulu1, Kevin Kennedy2, Salman Surangiwala3, Maggie Larche1, Jean Liew4, Mitchell Levine2, Graeme Reed5, Naira Ikram6, Carly Harrison7, Richard Howard8, Rashmi Sinha9, Monique Gore-Massy10 and Jonathan Hausmann11, 1McMaster University, Hamilton, ON, Canada, 2McMaster University, Hamilton, Canada, 3Queen’s School of Medicine, Kingston, Canada, 4University of Washington, Seattle, 5Canadian Spondylitis Association, Vancouver, Canada, 6Duke University, Durham, 7Lupus Chat, NA, 8Spondylitis Association of America, Van Nuys, CA, 9SJIA Foundation, Cincinnati, 10Lupus Foundation of America, Brooklyn, NY, 11Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA

    Background/Purpose: The COVID-19 pandemic has exacerbated structural and systematic barriers in access to healthcare for racial and ethnic minorities. The impact of these increased barriers…
  • « Previous Page
  • 1
  • …
  • 863
  • 864
  • 865
  • 866
  • 867
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology